<DOC>
	<DOCNO>NCT01578668</DOCNO>
	<brief_summary>The purpose study determine whether erlotinib plus pemetrexed , cisplatin effective safe treat lung adenocarcinoma brain metastasis .</brief_summary>
	<brief_title>Erlotinib Plus Pemetrexed Treat Lung Adenocarcinoma With Brain Metastases</brief_title>
	<detailed_description>Non-small lung cancer ( NSCLC ) lead cause death world . Brain metastasis frequent complication NSCLC , especially lung adenocarcinoma . 30-50 % patient develop brain metastasis first time treatment . Limited treatment option , whole brain radiotherapy ( WBRT ) combine without stereotactic radiosurgery ( SRS ) primary treatment approach , available brain metastasis patient poor survival . So availability effective therapy therefore great importance . Currently , two agent ( erlotinib pemetrexed ) report effective lung adenocarcinoma patient brain metastasis . The heterogeneity NSCLC tumor provide strong rationale use combination therapy target agent different mechanism action , moreover different combination offering synergistic effect . So investigate erlotinib plus pemetrexed , cisplatin effective safe treat lung adenocarcinoma brain metastasis .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histological cytological diagnosis lung adenocarcinoma histology brain metastases 2 . 18 year old 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 3 ( poor PS cause neurological symptom ) 4 . Appraisable intracranial disease , presence least one lesion , long diameter &gt; 5 mm brain MRI 5 . Haemoglobin 10.0 g/dl , Absolute neutrophil count ( ANC ) 1.5^9/L , platelet 100 x 10^9/L 6 . Total bilirubin 1.5 x upper limit normal ( ULN ) 7. alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastases 8 . Creatinine clearance 60ml/min ( calculate accord Cockcroftgault formula ) 9 . If receive brain radiotherapy , patient include least 8 week end radiotherapy . 1 . Mixed nonadenocarcinoma cell lung cancer histology 2 . Previous treatment pemetrexed tarceva 3 . Be allergic pemetrexed tarceva</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>lung adenocarcinoma</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>erlotinib</keyword>
	<keyword>pemetrexed</keyword>
</DOC>